Bharat Book

Report On Early Toxicology: Markets and Approaches

Press Release   •   Oct 05, 2012 11:38 IST

Early toxicology testing is emerging as one of the mostsignificant areas of drug discovery. Toxicity is no longer something that can be left to the development stage, or just a small part of ADMET. Toxicity determinations are an integral part of all aspects of drug discovery & development.
 
 This report, Early Toxicology Markets and Approaches, focuses on markets for early toxicology testing services. The objective of this report is to focus the reader’s attention on the issues and opportunities related to early toxicology testing in drug discovery. It begins with an overview of drug discovery, ADMET, and early toxicology testing. It continues with some of the ways big pharmaceutical developers dealwith early toxicology. Several areas are covered, including: http://www.bharatbook.com/healthcare-market-research-reports/early-toxicology-markets-and-approaches.html
 
 For the purposes of reporting market size and growth forecasts, the report segments the market into the following:
 
In Silico Approaches
 Databases
 Data Mining Tools
 Modeling
 In Vitro Assays and Platforms
 Biochemical Assays
 Cellular Assays
 Instruments & Platforms
 In Vivo Testing
 Mice & Traditional Animals
 Zebrafish Models
 Other Animals
 Human Microdosing
 Early Tox Services
 In Silico Services
 In Vitro Services
 In Vivo Services
 
 Market analysis in this report considers primarily the availabilityof products, number and type of clinical trials active, primary endpoints, anddevelopment of new products. The marketfocuses on the United States region and, where available, discusses the marketglobally. All sales are displayed at the manufacturers’ level in U.S.dollars. Although the sales figures aredisplayed at the manufacturers’ level, in many instances, this figurerepresents a close comparison to the retail level as many end users are purchasing directly from the manufacturer.The base year is 2011, with forecasts provided for each year through 2016.  Business Report
 
 Early toxicology is done not only to discover problem compounds, but provide directions for compound development. Early toxicology gives more than just a yes/no answer. It provides predictions of how the compound will interactwith cells, tissues, organs, systems, and the whole human. It can also show howa cell responds to a candidate compound. Various in vivo, in vitro, and in silico approaches have been evolving ever since. The objective of this report is to focus the reader’s attention on the issues and opportunities related to early tox testing in drug discovery, including:
 
 Market Size of Segments and Subsegments within Toxicology
 Forecasts of Expected Future Revenue Growth
 Review of R&D Spending Trends
 Discussion of Various Big Pharma Approaches to Early Toxicology Testing
 Consideration of Emerging Tools and Techniques
 Revenues of Top Toxicology Service Companies
 The Views of Interviewed Experts in the Field
 The Key Competitors and their Product and Service Offerings.
 
 At first glance, drug discovery can appear to be a straightforward process of screening compound candidates, optimizing leads, performing pre-clinical evaluations and then, with these steps completed, clinical trials can begin. The reality is not so neat. These activities often overlap, merge, and conflict with each other. So ADME (Absorption, Distribution, Metabolism, Excretion) and Toxicology are not simply a step in lead optimization, they are actually an integral part of an ongoing process.
 
 The report begins with an overview of drug discovery, ADMET, and early tox testing. It continues with some of the ways big pharmas deal with early tox. The next four chapters deal with the markets for in-silico, in-vitro, and in-vivo early tox products, and with the suppliers of early tox services. Product, company and market information are provided in each of these chapters. Opinions of the experts on basic issues are provided in Chapter Seven. The report concludes with profiles of 30 representative suppliers, the products they provide and their approach to the market.
 
 CHAPTER ONE: EXECUTIVE SUMMARY
 
Drug Discovery: A Complex Process Viox
 Baycol
 Rezulin
 FenPhen
 Drug Development Summary
 Scope and Methodology
 Market Overview
 Competitors
 
 CHAPTER TWO: INTRODUCTION TO EARLY TOXICOLOGY
 
Overview
 The Cost of Drug Development
 The Role of Contract Research Organizations
 Toxicology Measurement Issues
 Alternative Approaches to Early Toxicity
 
 CHAPTER THREE: PHARMA STRATEGIES AND TOXICOLOGY TACTICS
 
Overview
 Abbott: Developing Their Own Tools
 Bristol-Myers Squibb: Reducing Drug Attrition
 Eli Lilly & Company: In Silico And In Vitro Methods
 Glaxo Smithkline: Global Safety Board
 Johnson &Johnson: Alliances And Biomarkers
 Novartis: Modeling & Simulation
 Pfizer: Collaborative Approach
 
 CHAPTER FOUR: IN SILICO APPROACHES: DATABASES AND MODELING
 
Background
 Databases
 Data Mining And Analysis
 In-Silico Modeling Standard Tests
 Commercial Modeling Products
 Advanced Chemistry Development (ACD)
 Bio-Rad
 GeneGo
 Gene Logic
 IDBS
 Ingenuity Systems
 KNIME
 Simulations Plus
 Predicting Toxicity With Qsars And Expert Modeling Systems
 Government Agency And Public Initiatives
 EPA’s NCCT and CompTox
 FDA
 
 For more information kindly visit :
 
Early Toxicology: Markets and Approaches
 
 Or
 
 Bharat Book Bureau
 Ph.: + 91 22 27810772 / 27810773
 Fax: + 91 22 27812290
 Email: info@bharatbook.com
 Website: www.bharatbook.com
 Follow us on twitter: http://twitter.com/#!/Sandhya3B
  http://bharatbookblog.wordpress.com/ 

Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.